EUROPE COMPANION DIAGNOSTICS MARKET 2022-2028

Description

MARKET OUTLOOK

CRI’s report infers that the companion diagnostics market in Europe is deemed to advance at a CAGR of 12.61% in value during the forecast years 2022-2028. Italy, Spain, France, Germany, Poland, the United Kingdom, and the Rest of Europe are evaluated in the market report.
In France, the majority of the population is supported by statutory health insurance overseen by the Hauté Autorite de Santé (HAS). In this regard, the national healthcare system in the country is considered to be considerate as it aims to reduce healthcare expenditure. The reduction in healthcare expenditure will ultimately reduce excess government spending. Due to high reimbursement coverage, the penetration of CDx is high in the country. Thus, such developments support the companion diagnostics market’s growth across the country.
Furthermore, Spain has been witnessing economic restraints over the past few years. This has made it imperative to reduce healthcare expenses. In this regard, CDx is executed in the outpatient hospital site. On the other hand, hospitals directly negotiate with the manufacturer. The hospital funding system relies on the global budget since reimbursement coding is unavailable for CDx. Nevertheless, the rising efforts to reduce healthcare expenses will increase the need for cost-effective technologies for diagnostics, opening new avenues for the market.

COMPETITIVE OUTLOOK

The prominent companies in the companion diagnostics market consist of Abbott Laboratories, Arup Laboratories, Biocartis, Almac Group, GE Healthcare, and Roche Diagnostics.

TABLE OF CONTENTS

1. EUROPE COMPANION DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY INSIGHTS
2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS
2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY & SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.10. MARKET DRIVERS
2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING PREVALENCE OF PRECISION MEDICINES
2.11. MARKET CHALLENGES
2.11.1. WEAK REIMBURSEMENT FRAMEWORK
2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET OPPORTUNITY
2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK – BY MECHANISM
3.1. IN-SITU HYBRIDIZATION
3.2. POLYMERASE CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT GENERATION SEQUENCING
3.5. OTHER MECHANISMS
4. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK – BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS DISEASES
4.4. OTHER INDICATORS
5. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK – BY CONSUMER
5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE LABORATORIES
5.3. OTHER CONSUMERS
6. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK – BY COMMODITY
6.1. ASSAY KITS AND REAGENTS
6.2. SOFTWARE AND SERVICES
7. EUROPE COMPANION DIAGNOSTICS MARKET – COUNTRY OUTLOOK
7.1. UNITED KINGDOM
7.2. GERMANY
7.3. FRANCE
7.4. SPAIN
7.5. ITALY
7.6. POLAND
7.7. REST OF EUROPE
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT LABORATORIES
8.2. ALMAC GROUP
8.3. ARUP LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER CORPORATION
8.7. GE HEALTHCARE
8.8. GENOMIC HEALTH
8.9. ILLUMINA INC
8.10. MYRIAD GENETICS
8.11. QIAGEN
8.12. ROCHE DIAGNOSTICS
8.13. SYSMEX CORPORATION
8.14. THERMO FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY

LIST OF TABLES

TABLE 1: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF CONTRACTS & AGREEMENTS
TABLE 6: NUMBER OF CANCER PATIENTS IN 2020
TABLE 7: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: EUROPE COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: EUROPE COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)
FIGURE 8: EUROPE COMPANION DIAGNOSTICS MARKET, BY IMMUNOHOSTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: EUROPE COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: EUROPE COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: EUROPE COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: EUROPE COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: EUROPE COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: EUROPE COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)
FIGURE 19: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: EUROPE COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)
FIGURE 22: EUROPE COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 23: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: UNITED KINGDOM COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: GERMANY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: FRANCE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 27: SPAIN COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 28: ITALY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 29: POLAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 30: REST OF EUROPE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)